Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Primary high-risk HPV screening for cervical cancer in post-menopausal women.
Gyllensten U, Gustavsson I, Lindell M, Wilander E.
Gynecol Oncol. 2012 May;125(2):343-5. Epub 2012 Jan 28.
Related citations
Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS.
Gynecol Oncol. 2012 Apr;125(1):175-80. Epub 2012 Jan 9.
Summary of the Eurogin 2011 conference: Highlighting the recent advances in HPV-related cancers.
Nicol AF, Monsonego J.
Gynecol Oncol. 2011 Nov;123(2):179-81. No abstract available.
Gardasil™ HPV vaccination: surveillance of vaccine usage and adherence in a military population.
Shen-Gunther J, Shank JJ, Ta V.
Gynecol Oncol. 2011 Nov;123(2):272-7. Epub 2011 Aug 24.
Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.
Tropé A, Jonassen CM, Sjøborg KD, Nygård M, Dahl FA, Alfsen GC, Lie AK.
Gynecol Oncol. 2011 Nov;123(2):257-62. Epub 2011 Aug 12.
HPV molecular assays: defining analytical and clinical performance characteristics for cervical cytology specimens.
Shen-Gunther J, Yu X.
Gynecol Oncol. 2011 Nov;123(2):263-71. Epub 2011 Aug 11.
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.
Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EA, Baak JP.
Gynecol Oncol. 2011 Nov;123(2):278-83. Epub 2011 Aug 10.
Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications.
Valari O, Koliopoulos G, Karakitsos P, Valasoulis G, Founta C, Godevenos D, Dova L, Paschopoulos M, Loufopoulos A, Paraskevaidis E.
Gynecol Oncol. 2011 Sep;122(3):505-8. Epub 2011 Jun 12.
Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2.
del Pino M, Rodriguez-Carunchio L, Alonso I, Torné A, Rodriguez A, Fusté P, Castillo P, Nonell R, Abu-Lhiga N, Ordi J.
Gynecol Oncol. 2011 Sep;122(3):515-20. Epub 2011 May 31.
The use of an "old-fashioned method" to assess the clinical and economic impact of a HPV vaccination program.
Mennini FS, Capone A, Favato G.
Gynecol Oncol. 2011 Oct;123(1):175-6; author reply 177-8. Epub 2011 May 24. No abstract available.
Human papillomavirus (HPV) type distribution in cervical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women.
Correnti M, Medina F, Cavazza ME, Rennola A, Avila M, Fernándes A.
Gynecol Oncol. 2011 Jun 1;121(3):527-31. Epub 2011 Mar 21.
Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R.
Gynecol Oncol. 2011 Jun 1;121(3):505-9. Epub 2011 Mar 21.
Risk factors for HPV infection among American Indian and White women in the Northern Plains.
Bell MC, Schmidt-Grimminger D, Jacobsen C, Chauhan SC, Maher DM, Buchwald DS.
Gynecol Oncol. 2011 Jun 1;121(3):532-6. Epub 2011 Mar 17.
Age distribution of HPV genotypes in cervical intraepithelial neoplasia.
Sideri M, Igidbashian S, Boveri S, Radice D, Casadio C, Spolti N, Sandri MT.
Gynecol Oncol. 2011 Jun 1;121(3):510-3. Epub 2011 Mar 11.
Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S, Gasparini R, Panatto D, Demarteau N.
Gynecol Oncol. 2011 Jun 1;121(3):514-21. Epub 2011 Feb 19.
HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy.
Kang WD, Kim CH, Cho MK, Kim JW, Cho HY, Kim YH, Choi HS, Kim SM.
Gynecol Oncol. 2011 Jun 1;121(3):546-50. Epub 2011 Feb 21.
Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.
Kinney W, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE.
Gynecol Oncol. 2011 May 1;121(2):309-13. Epub 2011 Jan 26.
Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix.
Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, Buonaguro L, Buonaguro FM.
Gynecol Oncol. 2011 Apr;121(1):32-42. Epub 2011 Jan 6.
HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review.
Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS.
Gynecol Oncol. 2011 Mar;120(3):430-8. Epub 2010 Dec 4. Review.
Application of hTERC in thinprep samples with mild cytologic abnormality and HR-HPV positive.
Li Y, Zeng WJ, Ye F, Wang XY, Lü WG, Ma D, Wei LH, Xie X.
Gynecol Oncol. 2011 Jan;120(1):73-83. Epub 2010 Oct 28.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on